MicroPort® Receives Approval to Launch ARBORES™ Kyphoplasty Balloon Catheter in China

Shanghai MicroPort Medical (Group) Co., Ltd. (“MicroPort”) announced that its independently developed ARBORES™ Kyphoplastic Balloon Catheter (“ARBORES™”) was granted registration certificate from National Medical Products Administration of China (NMPA) recently.

As a core product for percutaneous kyphoplasty, ARBORES™ is used for the reduction of fractures and/or creation of a void in cancellous bone in the spine, along with the accessories such as balloon pump, puncture needle and dilator. The ARBORES™ approved by NMPA has six specifications, with the balloons ranging in length from 10mm to 20mm and featuring excellent crossability after being folded. The balloon dilation also demonstrates good support performance.

Previously, ARBORES™ was granted the CE Mark and entered the European Union market in 2017. The MicroPort product of Percutaneous Vertebroplasty Guided System, which is used in combination with ARBORES™, was also approved to launch in China in 2018. After the NMPA approval for ARBORES™, the balloon catheter product line of MicroPort has been significantly reinforced. Meanwhile, MicroPort is able to provide the doctors and patients with more comprehensive therapeutic solutions in the field of osteoporotic vertebral compression fracture.
MicroPort® Orthopedics Receives Approvals for Chinese-made Wedge-Shaped Femoral Stem and Metal Femoral Head

Suzhou MicroPort Joint MedTech Co., Ltd. recently received registration certificates for its independently developed hip implant components of wedge-shape femoral stem (“femoral stem”) and metal femoral head from National Medical Products Administration of China (NMPA).

The Chinese-made wedge-shape femoral stem is made of titanium alloy with a wedge shaped design, which features outstanding proximal femoral initial stability. The double tapered design of the femoral stem can effectively provide rotational stability and conserve bone stock. The titanium ion coated surface of the stem body is designed to offer more excellent bone apposition. The metal femoral head is made of CoCrMo with multiple models for clinical application, which can meet most of the clinical needs of hip arthroplasty.

The approved femoral stem can be used in combination with MicroPort® Orthopedics’ SuperPATH® Supercapsular Percutaneously Assisted Total Hip Arthroplasty (“SuperPATH™”). SuperPATH® is the world’s first minimally invasive hip posterior approach procedure. More patients can get back to their feet on the same day or even a few hours after the procedure, so that the recovery time is significantly cut to save perioperative costs. SuperPATH® has become the most advanced representative within the orthopedic fast recovery landscape.
MicroPort® MedBot’ 3D
Electronic Laparoscope Enters “Green Path”

On April 16, 2019, MicroPort MedBot (Shanghai) Co., Ltd. (“MicroPort® MedBot”), which is a subsidiary of Shanghai MicroPort Medical (Group) Co., Ltd. (“MicroPort®”), successfully applied for the entry of its independently developed 3D electronic laparoscope into the Special Review and Approval Procedure for Innovative Medical Devices (“Green Path”) with National Medical Products Administration of China (NMPA). By far, a total of 16 products of the subsidiaries of MicroPort® or its related companies have been granted entries into the Green Path.

Currently, 3D optical laparoscopes are mainstream internationally, with only a fraction of the laparoscope producers marketing 3D electronic laparoscopes. There is no 3D optical laparoscopes of domestic brands in the Chinese market, let alone 3D electronic ones. The 3D electronic laparoscope approved to enter the Green Path is independently designed and developed by MicroPort® MedBot, with the prospect of becoming the first Chinese-made 3D electronic laparoscope to obtain registration certificate. Compared to conventional 2D laparoscope, it uses dual image acquisition to provide surgeons with a three-dimensional vision and perception of depth during operations, which plays a highly important part in helping with the fine operations under laparoscope, such as hand-sewn operations, fine anastomosis and function reconstruction, in addition to hand switch of needle instrument and knotting. Meanwhile, by taking advantage of a vision closer to three-dimensional real situation, surgeons have more convenience in operations and shorter learning curves, which makes the 3D electronic laparoscope easier to master for the surgeons without any previous experience with laparoscopes [1]. MicroPort® MedBot closely pursues clinical needs during R&D, in that the application of an independently designed solution of high-definition objective lens and chip-on-tip structure ensures full high-definition output of dual image and gets rid of the huge optical structure of conventional laparoscopes to substantially reduce lens weight at the same time. As a result, not only surgeons’ needs for precious identification of tissue details are satisfied, but the intraoperative grip experience is also optimized significantly.
MicroPort® Attends 24th Cardiovascular Summit TCTAP 2019 in Korea

From April 27 to 30, the 24th Cardiovascular Summit TCTAP 2019 was held at the COEX Convention & Exhibition Center of Seoul, South Korea, bringing together healthcare professionals in the areas of cardiology, radiology and vascular surgery from across the world. MicroPort® sponsored the satellite conference of “My Clinical Experience with MicroPort® Latest Technology” to host themed lectures and case presentations to share and discuss with the healthcare professionals in attendance the clinical experiences on Firehawk® Rapamycin Target Eluting Coronary Stent System (“Firehawk®”). The other cutting-edge medical technologies of MicroPort® presented at the event were VitaFlow® Transcatheter Aortic Valve and Delivery System (“VitaFlow®”), which was close to launch, and Firesorb® Biodegradable Rapamycin Target Eluting Coronary Scaffold System (“Firesorb®”), which was still under development.

As one of the most important markets in the Asia-Pacific region, South Korea provides a promising outlook for medical devices. MicroPort® has boosted its exploration of the South Korean market by showcasing the Firehawk® clinical applications in Asia-Pacific region and presenting the biodegradable vascular stent system and transcatheter aortic valve replacement at TCTAP 2019. In the future, MicroPort® will commit to introducing more high-quality and high-end medical device products and services to South Korea and providing more comprehensive therapeutic solutions for local patients.
MicroPort® Attends the 2019 Inaugural World Health Expo

The first edition of World Health Expo ("the Expo") was held at the Wuhan International Expo Center recently. The Expo was guided by the National Health Committee of China and the People’s Government of Hubei Province, and hosted by the Wuhan Municipal People’s Government. With a theme of “A Healthy Future Driven by Science and Technology,” the Expo aimed to address the future development trend of the healthcare industry and feature the most cutting-edge healthcare science and technology as well as most representative healthcare corporations, products and business models. The Expo attracted over 4,000 exhibitors and over 200,000 visitors. MicroPort® presented at the Expo over 60 innovative products in the fields of cardiovascular intervention, orthopedics, cardiac rhythm management, structural heart diseases, neurovascular intervention, diabetics and endocrine diseases, and rehabilitation, which attracted huge attention.

The Expo contained an approximate 100 high-end forums and was attended by political leaders from the “Belt and Road” countries, world-renowned Nobel Prize laureates, academicians and healthcare experts and scholars, major leaders from state ministries, provinces and municipalities, and healthcare professionals from the hospitals affiliated to the Wuhan Municipal People's Government and from provincial and municipal medical insurance authorities. The joint MicroPort® booth was a focal point of visits, consultation and exchanges from the leaders and experts attending the Expo. Local news outlets took great interest in and covered the independently developed key products of MicroPort®, such as Firehawk® Rapamycin Target Eluting Coronary Stent System, Firebird2® Rapamycin-Eluting Coronary CoCr Stent System, Rega® Family Implantable Pacemakers, EVOLUTION® Medial-Pivot Total Knee Replacement System and SuperPath® Supercapsular Percutaneously Assisted Total Hip Arthroplasty.
China Interventional Therapeutics (CIT) 2019: Innovative Products of MicroPort® Muster on Display

The 17th edition of China Interventional Therapeutics (CIT 2019) was unveiled at China National Convention Center in Beijing, China, on March 28, 2019. This edition of CIT followed the theme of “The Next Ten Years - Cooperation, Innovation, Transition” and gathered the global healthcare professionals in the field of PCI to discuss the cutting-edge scientific topics. MicroPort® attended the event with the innovative products in the fields of interventional cardiology, structural heart disease therapy, cardiac rhythm management (CRM), and endovascular and peripheral vascular disease therapy. MicroPort® hosted a series of events such as satellite symposiums and forum for young and middle-aged doctors, which caught wide attention from the healthcare professionals at CIT 2019.

During CIT 2019, the joint booth of MicroPort® mainly displayed the cardiovascular products, which were joined by the products in the business segments of CRM and electrophysiology, structural heart diseases, and endovascular and peripheral vascular diseases. The joint booth comprehensively presented multiple innovative research results of MicroPort® in the interventional areas. MicroPort® also sponsored the Primary Scene Livestreaming, which gathered top-tier healthcare professionals to discuss and give in-depth analysis of cutting-edge technology topics in the field, providing very important guidance for the clinical practice of cardiovascular interventionalists. Meanwhile, MicroPort® particularly invited PCI healthcare professionals from various provinces and cities to take part in interviews on their satisfaction about the company’s products. The in-depth interviews collected feedbacks and clinical demands on the products in efforts to continuously improve the products in line with the actual needs of the clinicians.
**MicroPort® CardioFlow Attends the Fifth Edition of China Valve (Hangzhou) 2019**

The fifth edition of China Valve (Hangzhou) 2019 was held from April 19 to 21, 2019. MicroPort Shanghai CardioFlow Medtech Co., Ltd. ("MicroPort CardioFlow") presented at the conference its independently developed VitaFlow® Transcatheter Aortic Valve and Delivery System ("VitaFlow") and VitaFlow® II Transcatheter Aortic Valve and retrievable Delivery System ("VitaFlow® II"), which attracted wide attention.

This year’s edition added a new session of Global Live Demo that brought together top valvular heart teams worldwide. MicroPort® CardioFlow teamed up with Second Affiliated Hospital, Zhejiang University School of Medicine and Zhongshan Hospital Affiliated to Fudan University respectively to livestream two smooth operations of the second-generation clinical trial of VitaFlow® II. The outstanding post-operative clinical results gave rise to heated discussions between the doctors who performed the operations and the viewers.

During the New Device session on the afternoon of April 21, Prof. Daxin Zhou from Zhongshan Hospital Affiliated to Fudan University spoke of VitaFlow® II. VitaFlow® II inherits the unique motorized handle design of VitaFlow*. It can be completely recaptured before 75% deployment. The reinforced inner and outer shafts still retain flexibility and can be bent 360 degrees. The product also innovatively introduces the integrated sheath to widen the range of the sizes of access artery and effectively reduces the incidence rate of vascular complications. In addition, VitaFlow® II is accompanied with balloon dilation catheter and introducer set to provide the patients suffering severe aortic stenosis and doctors with a comprehensive integrated therapeutic solution. As a result, the safety and efficacy of the procedure are increased.
MicroPort® Wins the Title of Shanghai Municipality Model Unit for Six Consecutive Years

The 2019 Shanghai Municipality Spiritual Civilization Building Work Conference was held at the Shanghai Exhibition Center on April 10. The results of the 19th edition of Shanghai Municipality Model Unit Selection (2017-2018) were announced by Shanghai Municipality Spiritual Civilization Building Committee at the conference. MicroPort® continued to be awarded the honorary title of Shanghai Municipality Model Unit, making MicroPort® a holder of the title for six consecutive years.

The honor of being named as Shanghai Municipality Model Unit for six consecutive years represented a complete endorsement from the government and all walks of life of the strenuous efforts made by MicroPort® with respects to scientific management, original innovation, culture building, employee quality and social responsibility. In the future, MicroPort® will fully play the model and leading role of a Model Unit, against the backdrop of Shanghai’s campaign to build a scientific and technological innovation center, to make an all-out effort to create an environment for innovation in R&D. MicroPort® will also continuously make new contributions to further promote a high-quality development of Shanghai’s healthcare industry.
MicroPort® Makes the List of Top 20 Companies with Outstanding Contribution to Pudong New Area’s Scientific and Technological Innovation in 2018

On April 2, 2019, the Award Ceremony for Companies with Outstanding Contribution to Pudong New Area’s Economy in 2018 was held at Shanghai International Convention Center. Officials from the Communist Party Committee, Government, Standing Committee of the People’s Congress and CPPCC Committee of Pudong New Area attended the ceremony. MicroPort® was named as Top 20 Companies with Outstanding Contribution to Pudong New Area’s Scientific and Technological Innovation.

As a leading innovation-driven, high-end Chinese medical device group growing in Zhangjiang of Pudong, MicroPort® put a strong focus on independent innovation and consistently invests in research and development with high intensity. MicroPort® currently holds over 3,500 patents or patent applications (including 2,000 items overseas), and is a five-time winner of China National Science and Technology Progress Awards (including one award for corporate innovation platform models) and a multiple-time winner of the science and technology progress awards at province and ministry levels. As of December 2018, a total of 15 products have been granted entries into the Special Review and Approval Procedure for Innovative Medical Devices (the “Green Path”). MicroPort® respects and follows evidence-based medicine, with the clinical effects (expertise) of almost all of its core products and solutions having been published in the world’s mainstream scientific journals. Thus far, MicroPort® has released about 300 products to the market. The products have entered nearly 10,000 hospitals globally, covering Asia Pacific, Europe, and the Americas. We estimate that every 8 seconds a patient is being implanted with a MicroPort® manufactured device to save a life, improve the quality of a life, or create a new life. MicroPort® was highly recognized by all walks of life for its R&D capacity of core technology and innovative products, while it was named as Top 20 Companies with Outstanding Contribution to Pudong New Area’s Scientific and Technological Innovation in 2018.
For more information, please contact:

**Martin Sun**
Chief Financial Officer
MicroPort Scientific Corporation
Tel: (86)(21) 38954600
Email: ir@microport.com

**Leanne Li**
Board Secretary & VP of Corporate General Affairs
MicroPort Scientific Corporation
Tel: (86)(21) 38954600
Email: ir@microport.com